Greenphire Appoints UK-based Global Product Manager
News Feb 21, 2013
Greenphire has announced its first UK-based appointment of Rory O’Hare as Global Product Manager. This strategic appointment will enable Greenphire to leverage its existing core expertise in both the UK and European markets.
In this new role, Rory will be responsible for global requirements across all products including product positioning and sales support.
Rory will liaise between the European business and US headquarters to elevate Greenphire’s global footprint in the clinical trials industry.
O’Hare is an IT professional with 20 years’ experience in a variety of industries with a particular focus on Health Care for the last eight years.
He has completed several assignments for the Irish Health Service Executive (HSE) and ICON plc.
He has a BSc in Computing Science and a Masters in Business Administration and has held senior IT managerial positions for companies such as Borland and Xerox.
A high level industry executive, O’Hare has built up extensive managerial and consultancy expertise and demonstrated his ability working with clients including Dell, AOL and GE.
O’Hare joins Greenphire from ICON where, as IT Consultant, he designed and implemented payment solutions for the CRO.
Kyle Cunningham, Vice President of Product Management, Greenphire, comments, “In recent years, the Company has grown significantly and this first UK appointment underpins our growth strategy into Europe and beyond. A planned UK office in the first half of 2013 marks the next stage of Greenphire’s continued investment to grow its global footprint. We are delighted to welcome Rory to Greenphire and are confident his experience will make him a key member of our expanding team.”
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE